Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 9,549 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of Care Treatment Clear all
Withdrawn Phase 1 Interventional

Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation

NCT05720624
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm
Interventions
Anhydrous Enol-oxaloacetate, Best Practice, Biospecimen Collection, Magnetic Resonance Spectroscopic Imaging, Questionnaire Administration
Drug · Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Pilocarpine After Combined Cataract/Trabectome Surgery

NCT04005079
View directory record Official record
Conditions
Open Angle Glaucoma, Ocular Hypertension
Interventions
Pilocarpine, Ofloxacin, Prednisolone
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
30 Years to 100 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2022 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Early Integration of Palliative Care Using the BEACON PROQOL in Patients With High Grade Glioma and Their Caregivers

NCT04630379
View directory record Official record
Conditions
Glioblastoma, Malignant Glioma, WHO Grade III Glioma
Interventions
Palliative Therapy, Quality-of-Life Assessment, Supportive Care, Survey Administration
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2 Interventional

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

NCT03808662
View directory record Official record
Conditions
TNBC - Triple-Negative Breast Cancer, Triple Negative Breast Cancer, NSCLC, NSCLC Stage IV, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, NSCLC Stage IV Without EGFR/ALK Mutation
Interventions
Sterotactic Body Radiotherapy/SBRT, Standard of care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

IL-4 and Insulin Resistance for Treatment of Patients With Atopic Dermatitis

NCT05372003
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Photo therapy
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 26, 2024 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional Results available

Comprehensive Postpartum Management for Women With Hypertensive Disorders of Pregnancy

NCT05849103
View directory record Official record
Conditions
Hypertension, Pregnancy-Induced, Postpartum Preeclampsia, Hypertension; Maternal
Interventions
Blood Pressure Control Targets, Hypertension Management
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed No phase listed Observational

Studying Biomarkers in Patients With Pancreatic Cancer

NCT00900003
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
protein analysis, laboratory biomarker analysis
Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
Not listed
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Phase 4 Interventional

A Clinical Trial on the Use of Lidocaine Infusion During Surgery for Pediatric Upper Extremity Fractures and Its Impact on Total Perioperative Opioid Requirements

NCT07552766
View directory record Official record
Conditions
Fracture Arm, Fracture Closed of Lower End of Forearm, Unspecified, Fracture Elbow, Fracture Fixation, Fracture Fixation, Internal, Fracture Forearm, Fracture Distal Radius
Interventions
Lidocaine Infusion, Standard of Care (SOC)
Drug · Other
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

The Z Stitch Early Bed Rest Assessment Study

NCT06087497
View directory record Official record
Conditions
Atrial Fibrillation, Atrial Flutter, Supraventricular Tachycardia, Syncope, Ventricular Tachycardia
Interventions
Early mobilization
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 1 Interventional

Assessing Impact of Early Physiotherapy on Lymphatic Dysfunction in Head and Neck Cancer Survivorship

NCT05937269
View directory record Official record
Conditions
Lymphedema of Face, Head and Neck Cancer
Interventions
Near-infrared fluorescence lymphatic imaging, advanced pneumatic compression therapy
Combination Product · Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Terminated Phase 1 Interventional

Treating Acute Pancreatitis With Dabigatran, a Pilot Study

NCT03807856
View directory record Official record
Conditions
Acute Pancreatitis
Interventions
Dabigatran Etexilate Mesylate, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 30, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

Harm Reduction for Tobacco Smoking With Support of Tobacco-Replacing Electronic Nicotine Delivery Systems

NCT03962660
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
HaRTS-TRENDS, Standard Care (SC)
Other
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 24, 2019 · Synced Sep 30, 2026, 6:54 AM EDT
Not listed Not applicable Interventional

'M'-Technique, Guided Imagery, or Standard of Care on Anxiety and Pain Pre- & Post-operatively in Elective Joint Replacement Patients

NCT01874379
View directory record Official record
Conditions
Hip or Knee Replacement
Interventions
'M'-Technique®, Guided Imagery, Standard of Care
Other
Lead sponsor
Saint Clare's Health System
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Denville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 11, 2013 · Synced Sep 30, 2026, 6:54 AM EDT
Completed Not applicable Interventional

Vascular Changes of Rotator Cuff Repair Augmented With a Whole Blood Fibrin Clot

NCT03577379
View directory record Official record
Conditions
Rotator Cuff Tear
Interventions
Whole Blood Fibrin Clot
Other
Lead sponsor
Santa Barbara Cottage Hospital
Other
Eligibility
18 Years to 69 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCT

NCT06149403
View directory record Official record
Conditions
MPS-IH (Hurler Syndrome)
Interventions
Experimental: OTL-203, Active Comparator: Allo-HSCT
Genetic
Lead sponsor
Orchard Therapeutics
Industry
Eligibility
28 Days to 30 Months
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Not applicable Interventional

Utilization of Lung Ultrasound Score in Decision for Minimally Invasive Surfactant Administration

NCT07442669
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn, Respiratory Distress Syndrome in Premature Infant
Interventions
Lung ultrasound
Diagnostic Test
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
27 Weeks to 34 Weeks
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Results available

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266
View directory record Official record
Conditions
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Cediranib, Cediranib Maleate, Computed Tomography, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Questionnaire Administration, Topotecan, Topotecan Hydrochloride
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
370
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 285 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Phase 3 Interventional

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

NCT07225270
View directory record Official record
Conditions
Ovarian Cancer, Platinum-sensitive Ovarian Cancer, PSOC
Interventions
Rina-S, Bevacizumab
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
544 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
5
States / cities
Miami, Florida • Sarasota, Florida • Towson, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Recruiting Phase 2 Interventional

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

NCT06834373
View directory record Official record
Conditions
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory ALK-Positive Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Intravascular Large B-Cell Lymphoma, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chimeric Antigen Receptor T-Cell Therapy, Computed Tomography, Golcadomide, Leukapheresis, Positron Emission Tomography, Rituximab
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Clinical Validation of Non-Contact Vital Signs

NCT07362641
View directory record Official record
Conditions
Vital Sign Evaluation
Interventions
SmartSpectra Vital Signs Monitor measurement
Device
Lead sponsor
Presage Technologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Not yet recruiting Not applicable Interventional

MH-Rx Study (Baby on Board: Check-in on You, Your Medication, & Your Blood Pressure)

NCT07842341
View directory record Official record
Conditions
Hypertensive Disorders of Pregnancy, Chronic Hypertension in Pregnancy, Gestational Hypertension
Interventions
Community Health Worker (CHW)/Social Worker (SW)-led non-medical health related needs (NMHRN) intervention + Clinician-Led Medication Therapy Management (MTM) with remote blood pressure monitoring, Active Comparator (Control group)
Behavioral
Lead sponsor
Texas Southern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Sep 30, 2026, 6:54 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Allogeneic Human Mesenchymal Stem Cell Injection in PAtieNts With FaceTogenic Back Pain

NCT03487731
View directory record Official record
Conditions
Facetogenic Back Pain, Back Pain
Interventions
Allogeneic Human Mesenchymal Stem Cells (hMSCs), Placebo
Biological · Drug
Lead sponsor
Joshua M Hare
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2020 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Not applicable Interventional

3 Tesla MRI in Patients With Bladder Cancer

NCT00938145
View directory record Official record
Conditions
Bladder Cancer
Interventions
Specimen Ultra-High field MRI, chemotherapy, Cystectomy and Lymphadenectomy
Procedure · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Sep 30, 2026, 6:54 AM EDT
Active, not recruiting Phase 3 Interventional

Pre-operative SRS or Post-operative SRS in Treating Cancer Patients With Brain Metastases

NCT03741673
View directory record Official record
Conditions
Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 30, 2026, 6:54 AM EDT